NPM1 and FLT3 Test sale cost 2400 AED
Minimal Residual Disease MRD Analysis for T-ALL Test sale cost 3160 AED Minimal Residual Disease MRD Analysis for T-ALL Test Cost 3,510 د.إ Original price was: 3,510 د.إ.3,160 د.إCurrent price is: 3,160 د.إ.
17 - Hydroxy-Corticosteroids and 17 - Ketosteroids 24 Hour Urine Test sale cost 2820 AED 17 - Hydroxy-Corticosteroids and 17 - Ketosteroids 24 Hour Urine Test 3,130 د.إ Original price was: 3,130 د.إ.2,820 د.إCurrent price is: 2,820 د.إ.
Sale!

NPM1 and FLT3 Test Cost

Original price was: 3,200 د.إ.Current price is: 2,400 د.إ.

-25%

The NPM1 and FLT3 test is a specialized genetic test conducted to detect mutations in the NPM1 and FLT3 genes, which are often associated with acute myeloid leukemia (AML). This test is crucial for the diagnosis, prognosis, and determination of treatment strategies for patients with AML. The NPM1 gene mutation generally indicates a better response to certain treatments and a more favorable prognosis, whereas FLT3 mutations, particularly the internal tandem duplications (ITD), are associated with a higher risk of relapse and a poorer prognosis.

Performed at DNA Labs UAE, a leading facility in genetic testing, the test involves analyzing the patient’s DNA to identify any mutations in these genes. The process is meticulous and requires specialized equipment and expertise to ensure accurate results. The cost of the NPM1 and FLT3 test at DNA Labs UAE is 2400 AED, reflecting the comprehensive nature of the analysis and the critical insights it provides into the patient’s condition. This test is a valuable tool in the personalized treatment planning for AML patients, helping healthcare providers to tailor therapies that offer the best chances of success based on the genetic makeup of the leukemia.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

NPM1 and FLT3 Test Cost AED: 2400.0 – Symptoms, Diagnosis, and Details

Test Name: NPM1 and FLT3 Test

Components: EDTA Vacutainer (2ml)

Price: 2400.0 AED

Sample Condition: Bone marrow / Peripheral blood (Transport immediately)

Report Delivery: 7-8 days

Method: Sanger Sequencing

Test Type: Genetics

Doctor: Gynecologist

Test Department: Pre Test Information

NPM1+FLT3 can be done with a doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

NPM1 and FLT3 are two genes that are often mutated in acute myeloid leukemia (AML). NPM1 (Nucleophosmin 1) is a gene that encodes for a protein involved in various cellular processes, including ribosome biogenesis and DNA repair. Mutations in the NPM1 gene are commonly found in AML and are associated with a favorable prognosis. These mutations result in the production of a mutant NPM1 protein that is localized in the cytoplasm instead of the nucleus. NPM1 mutations are often used as a diagnostic marker for AML.

FLT3 (FMS-like tyrosine kinase 3) is a gene that encodes for a receptor tyrosine kinase involved in cell growth and differentiation. Mutations in the FLT3 gene are also commonly found in AML and are associated with a poor prognosis. The most common FLT3 mutation is an internal tandem duplication (ITD) in the juxtamembrane domain, which leads to constitutive activation of the FLT3 receptor. Other FLT3 mutations, such as point mutations in the tyrosine kinase domain, can also occur.

NPM1 and FLT3 mutations are often mutually exclusive in AML, meaning that patients with one mutation are unlikely to have the other. However, in some cases, patients can have both mutations, which may have implications for prognosis and treatment response. The presence of an NPM1 mutation without a FLT3 mutation is associated with a favorable prognosis, while the presence of a FLT3 mutation, especially with an ITD, is associated with a poor prognosis.

Targeted therapies have been developed to specifically inhibit the FLT3 receptor in AML patients with FLT3 mutations. These drugs, such as FLT3 inhibitors, have shown promising results in clinical trials and are being used in the treatment of AML patients with FLT3 mutations. However, there are currently no targeted therapies specifically approved for the treatment of AML patients with NPM1 mutations.

Test Name NPM1andFLT3 Test
Components EDTA Vacutainer (2ml)
Price 2400.0 AED
Sample Condition Bone marrow \/ Peripheral blood (Transport immediately)
Report Delivery 7-8 days
Method Sanger Sequencing
Test type Genetics
Doctor Gynecologist
Test Department:
Pre Test Information NPM1+FLT3 can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

NPM1 and FLT3 are two genes that are often mutated in acute myeloid leukemia (AML).

NPM1 (Nucleophosmin 1) is a gene that encodes for a protein involved in various cellular processes, including ribosome biogenesis and DNA repair. Mutations in the NPM1 gene are commonly found in AML and are associated with a favorable prognosis. These mutations result in the production of a mutant NPM1 protein that is localized in the cytoplasm instead of the nucleus. NPM1 mutations are often used as a diagnostic marker for AML.

FLT3 (FMS-like tyrosine kinase 3) is a gene that encodes for a receptor tyrosine kinase involved in cell growth and differentiation. Mutations in the FLT3 gene are also commonly found in AML and are associated with a poor prognosis. The most common FLT3 mutation is an internal tandem duplication (ITD) in the juxtamembrane domain, which leads to constitutive activation of the FLT3 receptor. Other FLT3 mutations, such as point mutations in the tyrosine kinase domain, can also occur.

NPM1 and FLT3 mutations are often mutually exclusive in AML, meaning that patients with one mutation are unlikely to have the other. However, in some cases, patients can have both mutations, which may have implications for prognosis and treatment response. The presence of an NPM1 mutation without a FLT3 mutation is associated with a favorable prognosis, while the presence of a FLT3 mutation, especially with an ITD, is associated with a poor prognosis.

Targeted therapies have been developed to specifically inhibit the FLT3 receptor in AML patients with FLT3 mutations. These drugs, such as FLT3 inhibitors, have shown promising results in clinical trials and are being used in the treatment of AML patients with FLT3 mutations. However, there are currently no targeted therapies specifically approved for the treatment of AML patients with NPM1 mutations.

SKU: TEST-4803